Urelumab
Urelumab
Urelumab (pronounced: yoo-REH-loo-mab) is a fully human monoclonal antibody that is designed to bind to the CD137 protein, which is a costimulatory receptor found on the surface of T cells. It is used in the field of oncology to enhance the immune response against cancer cells.
Etymology
The name "Urelumab" follows the INN naming convention for monoclonal antibodies. The "-mab" suffix indicates that it is a monoclonal antibody, while the "u-" prefix denotes that it is fully human. The "relu-" stem is used for agents that interact with the immune system.
Mechanism of Action
Urelumab binds to the CD137 protein, a member of the tumor necrosis factor receptor superfamily. This binding enhances the immune response by promoting the proliferation and activity of T cells, which play a crucial role in the body's immune response against cancer cells.
Related Terms
- Monoclonal antibody: A type of protein made in the lab that can bind to substances in the body, including cancer cells.
- CD137: A protein found on the surface of T cells that plays a crucial role in regulating immune response.
- T cells: A type of white blood cell that is of key importance to the immune system and is at the core of adaptive immunity, the system that tailors the body's immune response to specific pathogens.
- Oncology: The study and treatment of tumors.
External links
- Medical encyclopedia article on Urelumab
- Wikipedia's article - Urelumab
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski